# Phase 3 Study of MAP0004 in Adult Migraineurs

> **NCT00623636** · PHASE3 · COMPLETED · sponsor: **Allergan** · enrollment: 902 (actual)

## Conditions studied

- Migraine Disorders

## Interventions

- **DRUG:** MAP0004
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00623636
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2010-12
- **Final completion:** 2011-01
- **Target enrollment:** 902 (ACTUAL)
- **Last updated:** 2014-01-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00623636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00623636, "Phase 3 Study of MAP0004 in Adult Migraineurs". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00623636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*